743652
Last Update Posted: 2012-03-15
Recruiting has ended
All Genders accepted | 42 Days-5 Years |
373 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.
Eligibility
Relevant conditions:
Pneumococcal Disease
13-valent Pneumococcal Vaccine
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov